Powerful insights to guide efficient, personalised treatment decisions

Like every person, every tumour is unique. Our portfolio of extensively validated comprehensive genomic profiling* services provides powerful insights to to guide efficient, personalised treatment decisions at optimal times beneficial to your patients’ journeys.1–9

A comprehensive approach to genomic profiling

The Foundation Medicine comprehensive genomic profiling approach broadly analyses the tumour genome to identify clinically relevant genomic alterations and signatures, and potentially expands patients’ treatment options.1,2.4-6,8-14 Clinicians then receive a clear, in-depth report that supports clinical decisionmaking by providing insights on the patient's genomic profile as well as associated targeted therapies and immunotherapies,† as well as relevant clinical trials.15

A high-quality portfolio of services

Our portfolio of extensively validated comprehensive genomic profiling services provide powerful insights to guide efficient, personalised treatment decisions at optimal times beneficial to your patients’ journeys.1–9

Overview of services

Combined commitment

*Comprehensive genomic profiling is a next-generation sequencing approach able to detect both novel and known variants, including all classes of genomic alterations (base substitutions, insertions and deletions, copy number alterations and rearrangements) and genomic signatures (for example Tumor Mutational Burden [TMBJ and blood Tumour Mutational Burden [bTMB], Microsatellite Instability [MSI] or Loss of Heterozygosity [LoH]), to provide prognostic, diagnostic and predictive insights that inform treatment decisions for individual patients across all cancer types (CGP insights can be generated either from an end-to-end, curated reporting service or through in-house testing solutions).

†Approved therapies are ranked alphabetically within NCCN therapy categories (for additional information on the NCCN categories please refer to the NCCN Compendium* at www.nccn.org).

‡Clinical validation demonstrated concordance with the following companion diagnostics: cobas® EGFR Mutation Test, Ventana ALK (DSF3) CDx Assay, Vysis ALK BreakApart FISH Probe Kit, therascreen® KRAS RGQ PCR Kit, Dake HER2 FISH PharmDx® Kit, cobas® BRAF V600 Mutation Test, THxlD® BRAF kit. For more information, please see the FoundationOne®CDx Technical Specifications available at: www.rochefoundationmedicine.com/f1cdxtech.

§Clinical validation demonstrated concordance with the following diagnostics: cobas® EGFR Mutation Test v2, a tumour tissue polymerase chain reaction-based clinical trial assay (CTA), and an externally validated circulating cell-free DNA-based next-generation sequencing assay. For more information please see the FoundationOne Liquid®CDx Technical Specifications available at: www.eifu.online/FMl/190070862.

¥TMB reported by FoundationOne CDx and FoundationOne Heme. bTMB reported by FoundationOne Liquid CDx. MSI reported by FoundationOne CDx and FoundationOne Heme, MSI-H reported by FoundationOne Liquid CDx.

bTMB, blood Tumour Mutational Burden; FDA, US Food and Drug Administration; FFPE, formalin-fixed paraffin-embedded; MSI, Microsatellite Instability; NCCN, National Comprehensive Cancer Network; NGS, next generation sequencing; LoH, Loss of Heterozygosity: TMB, Tumour Mutational Burden.